184.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BGNE Giù?
Forum
Previsione
Precedente Chiudi:
$183.81
Aprire:
$184
Volume 24 ore:
331.61K
Relative Volume:
0.91
Capitalizzazione di mercato:
$19.68B
Reddito:
$3.32B
Utile/perdita netta:
$-860.46M
Rapporto P/E:
-22.20
EPS:
-8.32
Flusso di cassa netto:
$-1.04B
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
-13.20%
1 anno Prestazione:
+24.33%
Beigene Ltd Adr Stock (BGNE) Company Profile
Nome
Beigene Ltd Adr
Settore
Industria
Telefono
13459494123
Indirizzo
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Confronta BGNE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BGNE
Beigene Ltd Adr
|
184.71 | 19.68B | 3.32B | -860.46M | -1.04B | -8.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-12-03 | Ripresa | Morgan Stanley | Overweight |
2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
2024-02-06 | Ripresa | JP Morgan | Overweight |
2023-09-12 | Iniziato | Macquarie | Outperform |
2023-08-17 | Iniziato | Jefferies | Buy |
2023-07-17 | Iniziato | Citigroup | Buy |
2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
2023-01-12 | Iniziato | Daiwa Securities | Buy |
2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-08-09 | Ripresa | JP Morgan | Overweight |
2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-02-07 | Iniziato | Deutsche Bank | Buy |
2021-10-12 | Iniziato | Bernstein | Outperform |
2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
2021-03-08 | Iniziato | China Renaissance | Buy |
2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
2020-07-10 | Downgrade | CLSA | Buy → Outperform |
2020-03-13 | Aggiornamento | Macquarie | Underperform → Neutral |
2020-02-18 | Ripresa | Goldman | Buy |
2020-01-17 | Aggiornamento | CLSA | Outperform → Buy |
2020-01-17 | Ripresa | Morgan Stanley | Overweight |
2019-12-16 | Downgrade | Guggenheim | Buy → Neutral |
2019-12-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
2019-11-19 | Downgrade | UBS | Buy → Neutral |
2019-11-13 | Downgrade | CLSA | Buy → Outperform |
2019-11-04 | Reiterato | Maxim Group | Buy |
2019-06-04 | Iniziato | Bernstein | Outperform |
2019-05-10 | Aggiornamento | CLSA | Outperform → Buy |
2019-03-15 | Iniziato | BofA/Merrill | Buy |
2019-01-04 | Downgrade | CLSA | Buy → Outperform |
2018-11-21 | Iniziato | JP Morgan | Overweight |
2018-09-25 | Iniziato | Leerink Partners | Outperform |
2018-05-17 | Reiterato | Maxim Group | Buy |
Mostra tutto
Beigene Ltd Adr Borsa (BGNE) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene’s president Wu Xiaobin sells $13.6 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com
CLSA Expects BEIGENE to Achieve Operating Breakeven This Yr; TP Sharply Raised to $209.8 - AASTOCKS.com
BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa
BeiGene stock price target raised to $334 at TD Cowen - Investing.com
BeiGene stock target raised to $308 on strong FY results - Investing.com India
Beigene Ltd Adr Azioni (BGNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):